Asthma is a heterogeneous disease characterized by airway inflammation resulting from
complex interactions between multiple hosts as well as environmental factors. As a chronic …

Objective Tiotropium is a long-acting muscarinic antagonist approved for maintenance
treatment of asthma in children, adolescents, and adults in the United States, and …

Tiotropium is a long-acting muscarinic antagonist (LAMA) that exerts its bronchodilatory
effect by blocking endogenous acetylcholine receptors in the airways. Its safety and efficacy …

Asthma is a chronic disease of airway inflammation with a large global burden. Despite
established, guideline‐based stepwise therapy, a significant proportion of patients remain …

Introduction The objective of this paper is to systematically review the existing evidence of
the effectiveness and safety profile of a long-acting inhaled muscarinic antagonist as add-on …

Severe and poorly controlled asthma still accounts for a great portion of the patients affected.
Disease control and future risk management have been identified by international …

Despite the availability of a range of treatment options and management guidelines, a high
proportion of adults with asthma remain uncontrolled. The challenge of managing …

Severe asthma is associated with substantial morbidity and mortality. Therapies must be
maximized to gain control of a patient's severe asthma; however, avoiding overtreatment is …

Tiotropium bromide (Spiriva®) solution for inhalation via the Respimat® Soft Mist™ inhaler
is a long-acting anticholinergic agent approved in the EU for the add-on maintenance …

PURPOSE: To evaluate the safety of once-daily tiotropium (5 µg in the morning via
Respimat® Soft Mist™ Inhaler) for patients with symptomatic asthma despite standard …